Duke Clinical Research Institute

What do the results of the OCEANIC-AF trial tell us about the future of asundexian for atrial fibrillation?treatment? Watch as DCRI’s Manesh Patel, MD shared his thoughts on the trial after his presentation at this month’s #ESCCongress, and follow the DCRI YouTube page for future video content: https://lnkd.in/edNj9pDM #clinicaltrials #clinicalresearch #cardiology

The Drug-Induced Liver Injury Network (DILIN), which includes the DCRI as a network member, will be hosting a Virtual Herbal and Dietary Supplement Safety Surveillance Summit on Monday, Sept. 23. See below for the summit agenda and information on how to register: https://lnkd.in/e7hj23DB #clinicaltrials #clinicalresearch #liverhealth #herbaldrugs

During this year’s #ESCCongress, results from the STEEER-AF trial found better clinician education could lead to increased usage of guideline-directed care for patients with #Afib. DCRI’s Chris Granger says that while there is “an enormous need and opportunity” for better implementation, the question remains on how best to “scale [education intervention] to general practice settings.” https://lnkd.in/exGiQE3R #clinicaltrials #clinicalresearch

At this year’s #ESCCongress, data from the FINEARTS-HF trial showed how finerenone offered significant benefits in a population of?heart failure patients?with a left ventricular ejection fraction greater than 40%. On the latest episode of the Don't Miss a Beat podcast, DCRI’s Stephen Greene, MD joined his cohost and FINEARTS-HF investigator Muthu Vaduganathan, MD, MPH, to discuss finerenone in treatment algorithms for heart failure: https://lnkd.in/e6eTDdFb #clinicaltrials #clinicalresearch #heartfailure

Allyx Therapeutics has recently announced that the first Parkinson’s disease patient has been treated with their lead compound ALX-001 in a new trial led by the DCRI. The trial will assess safety, pharmacokinetics and potential therapeutic response in patients with the disease over a 28-day period. Learn more about the trial and the role DCRI is playing here: https://lnkd.in/dWVpduCb #clinicaltrials #clinicalresearch #Parkinsons #

Using digital tools is key to providing optimal care for a large — and growing — heart failure patient population, according DCRI Executive Director, Adrian Hernandez, MD, MHS at #ESCCongress. To do this, clinicians should: ? build better systems and automate ? leverage tools for patient engagement and automation ? continuously evaluate new tools #digitalhealth #cardiology #heartfailure

Earlier today at #ESCCongress, DCRI's Renato Lopes, M.D., Ph.D, lead author of GUARD-AF, presented the results of the study. “Atrial fibrillation is often undiagnosed and can increase the risk of ischemic stroke, which is largely reversible by oral anticoagulation,” said Dr. Lopes in a press release for Duke Health. “We still need definitive evidence that diagnosis of atrial fibrillation through systematic screening can lead to subsequent treatment with oral anticoagulation and therefore, lower stroke risk.” Read the full release here: https://lnkd.in/ez4SJkdY #cardiology #stroke #AFib

The final day of #ESCCongress is tomorrow! Catch our DCRI faculty and fellows presenting at these sessions.

Asundexian once daily was shown to be inferior to apixaban in preventing stroke and systemic embolism for patients with #AFib at high risk for stroke, according to results from the OCEANIC-AF trial presented by Manesh Patel, MD at #ESCCongress. “Over 14,810 patients with atrial fibrillation at risk for stroke were enrolled over 11 months worldwide. Asundexian 50mg once daily was inferior for the prevention of stroke and systemic embolism compared with apixaban in patients with atrial fibrillation at high risk for stroke...Clearly more research is needed to determine if there is the correct amount of Factor XI inhibition for this indication, atrial fibrillation and stroke prevention.” View the presentation slides: https://lnkd.in/epQYpYbm View the paper in the NEJM: https://lnkd.in/eyDRpZj2 #cardiology #stroke

“In patients with a history of atrial fibrillation, the Apple Watch IRN is most sensitive at the individual level. It is less sensitive at the episode level. The current IRN algorithm for the Apple Watch favors long episodes greater than six hours. Thus, the limited sensitivity, the user independence, the limited accuracy of the IRN algorithm invites caution when we’re interpreting those data to make clinical decisions for our patients with known atrial fibrillation.” -DCRI faculty Jonathan Piccini, MD, MHS at #ESCCongress 2024 on how well Apple Watches performed at detecting #AFib in a known patient population. #cardiology #hearthealth